期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

过氧化物酶体增殖激活受体γ激动剂与肾脏疾病研究进展

下载PDF
导出
作者 刘鹏 冼苏
机构地区 广西中医学院附属瑞康医院内分泌科
出处 《广西医学》 CAS 2007年第11期1724-1727,共4页 Guangxi Medical Journal
关键词 糖尿病肾病 慢性肾功能衰竭 过氧化物酶体增殖激活受体-γ激动剂
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献29

  • 1Stratton IM,Adler HA,Neil AW,et al.Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35):prospective observational study[J].British Medical Journal,2000,321(7258):405 -412.
  • 2Krentz AJ,Bailey CJ.Oral antidiabetic agents[J].Drugs,2005,65(3):385 -411.
  • 3Guan Y,Breyer MD.Peroxisome proliferator-activated receptors (PPARs):novel therapeutic targets in renal disease[J].Kidney International,2001,60(1):14 -30.
  • 4Staels B,Fruchart J.Therapeutic roles of peroxisome proliferator-activated receptor agonists[J].Diabetes,2005,54(8):2460 -2470.
  • 5Dormandy JA,Charbonnel B,Eckland DJ,et al.Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO-active Study (PRO spective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial[J].Lancet,2005,366(9 493):1279 -1289.
  • 6Chapelsky MC,Thompson-Culkin K,Miller AK,et al.Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency[J].Journal of Clinical Pharmacology,2003,43(3):252 -259.
  • 7Thompson-Culkin K,Zussman B,Miller AK,et al.Pharmacokinetics of rosiglitazone in patients with end-stage renal disease[J].Journal of International Medical Research,2002,30(4):391 -399.
  • 8Budde K,Neumayer HH,Fritsche L,et al.The pharmacokinetics of pioglitazone in patients with impaired renal function[J].British Journal of Clinical Pharmacology,2003,55(4):368 -374.
  • 9刘峰,王伟铭,陈楠.过氧化物酶体增殖物激活受体γ激动剂对TGF-β_1诱导肾成纤维细胞细胞外基质表达的影响[J].肾脏病与透析肾移植杂志,2006,15(1):30-34. 被引量：6
  • 10Yoshimoto T,Naruse M,Nishikawa M,et al.Antihypertensive and vasculo-and renoprotective effects of pioglitazone in genetically obese diabetic rats[J].Am J of Physiol,1997,272(6 Pt 1):989 -996.

二级参考文献16

  • 1Zeisberg M,Strutz F,Muller GA.Role of fibroblast activation in inducing interstitial fibrosis.J Nephrol,2000,13 (Suppl 3):S111-120.
  • 2Jernigan S,Wing D,Schnaper HW,et al.Effects of chronic blockade with soluble TGF-β receptor in rats with overload proteinuria(Abstract).J Am Soc Nephrol,1999,10:573A.
  • 3Kasuga H,Ito Y,Sakamoto S,et al.Effects of anti-TGF-beta type receptor antibody on experimental glomerulonephritis.Kidney Int,2001,60 (5):1745-1755.
  • 4Gupta S,Clarkson MR,Duggan J,et al.Connective tissue growth factor:potential role in glomerulosclerosis and tubulointerstitial fibrosis.Kidney Int,2000,58:1389-1399.
  • 5Guan YF,Breyer MD.Peroxisome proliferator-activated receptors(PPARs):novel therapeutic targets in renal disease.Kidney Int,2001,60:14 -30.
  • 6Zeng F,Fornoni A,Elliot SJ,et al.Upregulation of type Ⅰ collagen by TGF-β in mesangial cells is blocked by PPARγ activation.Am J Physiol.Renal Physiol,2002,282:639-648.
  • 7Baoling G,Daisuke K,Motohide I,et al.Peroxisome proliferatorsactivated receptor-γ ligands inhibit TGF-β1 -induced fibronectin expression in glomerular mesangial cells.Diabetes,2004,53(2):200-208.
  • 8Sawano H,Haneda M,Sugimoto T,et al.15-Deoxy-△12,14-prostaglandin J2 inhibits IL-1β-induced cyclooxygenase-2 expression in mesangial cells.Kidney Int,2002,61 (6):1957-1967.
  • 9Chang PC,Chen TH,Chang CJ,et al.Advanced glycosylation end products induce inducible nitric oxide synthase(iNOS) expression via a p38 MAPK-depeddent pathway.Kidney Int,2004.65(5):1664-1675.
  • 10Panzer U,Schneider A,Guan Y,et al.Effects of different PPARγ-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis.Kidney Int,2002,62 (2):455-464.

共引文献5

广西医学
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部